Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  • STATUS
    Not Recruiting
  • End date
    Oct 11, 2023
  • participants needed
    1100
  • sponsor
    Hoffmann-La Roche
Updated on 25 April 2021
ct scan
gonadotropin
prednisone
androgens
prednisolone
testosterone
metastasis
progressive disease
bone scan
abiraterone
orchiectomy
serum testosterone
castration-resistant prostate cancer
adenocarcinoma
adenocarcinoma of prostate
soft tissue disease
androgen ablation

Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Details
Condition Metastatic Prostate Cancer
Treatment Placebo, Abiraterone, Ipatasertib
Clinical Study IdentifierNCT03072238
SponsorHoffmann-La Roche
Last Modified on25 April 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note